Furthermore, several anti-PD-1 and PD-L1(B7-H1) antibodies have been approved for the treatment of an array of cancer types by The United States Food and Drug Administration (FDA), e.g., nivolumab (2014), pembrolizumab (2014), atezolizumab (2016), avelumab (2017), durvalumab (2017), cemiplimab (2018), dostarlimab (2021). Here, PDCD1 is linked to cancer.